Depomed buys suite of Janssen pain drugs for $1bn

16-01-2015

California-based pharmaceutical company Depomed has revealed it will acquire the IP rights to Janssen Pharmaceuticals’ painkiller drug Nucynta (tapentadol) for $1.05 billion.


Depomed, Janssen, Johnson & Johnson, Nucynta, M&A

LSIPR